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ABSTRACT
Motivation: A central problem in biomarker discovery from large-
scale gene expression or single nucleotide polymorphism (SNP)
data is the computational challenge of taking into account the
dependence among all the features. Methods that ignore the
dependence usually identify non-reproducible biomarkers across
independent datasets. We introduce a new graph-based semi-
supervised feature classiﬁcation algorithm to identify discriminative
disease markers by learning on bipartite graphs. Our algorithm
directly classiﬁes the feature nodes in a bipartite graph as
positive, negative or neutral with network propagation to capture
the dependence among both samples and features (clinical
and genetic variables) by exploring bi-cluster structures in a
graph. Two features of our algorithm are: (1) our algorithm
can ﬁnd a global optimal labeling to capture the dependence
among all the features and thus, generates highly reproducible
results across independent microarray or other high-thoughput
datasets, (2) our algorithm is capable of handling hundreds of
thousands of features and thus, is particularly useful for biomarker
identiﬁcation from high-throughput gene expression and SNP
data. In addition, although designed for classifying features, our
algorithm can also simultaneously classify test samples for disease
prognosis/diagnosis.
Results: We applied the network propagation algorithm to study
three large-scale breast cancer datasets. Our algorithm achieved
competitive classiﬁcation performance compared with SVMs and
other baseline methods, and identiﬁed several markers with clinical
or biological relevance with the disease. More importantly, our
algorithm also identiﬁed highly reproducible marker genes and
enriched functions from the independent datasets.
Availability: Supplementary results and source code are available at
http://compbio.cs.umn.edu/Feature_Class.
Contact: kuang@cs.umn.edu
Supplementary information: Supplementary data are available at
Bioinformatics online.
∗To whom correspondence should be addressed.
1 INTRODUCTION
Determiningthecausativefactorsofdiseaseiscriticalforimproving
clinical treatment and understanding the biological principles of
disease. Recent developments in high-throughput technology allow
large-scale measurement of genomic variations such as gene
expression and single nucleotide polymorphisms (SNPs) of a
population. Associating these genomic and genetic variations with
disease-related phenotypes provides good potential for elucidating
etiology of diseases (Rebbeck et al., 2007). It has also been shown
thatthediscoveredbiomarkerscanpossiblyprovidebetterprognosis
and diagnosis than the currently available clinical measures for risk
assessment of patients with various diseases (Gevaert et al., 2006;
van’t Veer et al., 2002). However, computational identiﬁcation of
biomarkers of disease from high-throughput genomic data is an
increasingly challenging problem. High-throughput data are both
expensive to generate and difﬁcult to obtain. Typically, only a small
number of samples are available for analyzing tens of thousands of
genes or even millions of SNPs. This analysis suffers from the curse
of ‘high-dimension and low-sample size’, the number of samples
being too limited to represent the class distribution of phenotypes.
Common statistical criteria for biomarker discovery are
correlation coefﬁcients (van’t Veer et al., 2002) and statistics used
with hypothesis testing methods such as the t-test and Wilcoxon
rank-sum test (Dudoit et al., 2002). These statistical methods rank
the features only based on their individual correlation with the
phenotypic label. Feature selection is a more general machine
learning approach for identifying biomarkers (Sun et al., 2007).
The objective of feature selection is to ﬁnd a (minimal) subset of
featuresthatcanmaximizethepredictionperformanceofaclassiﬁer.
However, the curse of dimensionality makes feature selection on
high-throughput data particularly hard and unstable. To maximize
the prediction performance of a classiﬁer, existing algorithms rely
on heuristic strategies searching for a sub-optimal feature set.
Moreover, the sub-optimal feature set might not be unique given
that there are many co-expressed genes or SNPs with high-linkage
disequilibrium, which have similar discriminative power. Thus,
feature selection algorithms often fail to reveal the modularity on
the features when used for biomarker identiﬁcation. Many other
supervised machine learning techniques have also been applied to
identify clinical and genetic markers of disease. These approaches
© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2023T.Hwang et al.
Graph labeling Predicted labels Clinical variables Gene expressions SNPs
AB CDE
Fig. 1. Feature classiﬁcation and disease-marker identiﬁcation on bipartite graphs. (A) This example shows a graph with six sample vertices and four feature
vertices.All the edges are assumed uniformly weighted. Four samples are initially labeled according to their phenotype class; the other two and all the feature
vertices are unknown and labeled 0. The optimal labels are given in the parentheses: the two feature vertices strongly connected to the negative vertices are
labeled negative, the one feature vertex strongly connected to the positive vertices is labeled positive, and the one that is connected to both classes is assigned
0. The two unlabeled samples are also labeled according to their connections in the graph. (B) The prediction scores (activation values) produced by network
propagation with α=0.5 and 1000 iterations on the graph in (A). All the nodes are correctly labeled; note that the labels are relaxed into real numbers. (C)A
bipartite graph with vertices of clinical variables. (D) A bipartite graph with vertices of gene expressions; the edge weights are the absolute expression levels
of the genes. (E) A bipartite graph with vertices of SNPs; all the edges are uniformly weighted by 1.
are typically variations of commonly used supervised learning
algorithms, such as SVMs (Zhang et al., 2006) and Bayesian
networks (Gevaert et al., 2006). However, these algorithms are not
directlydesignedforthepurposeofsupervisedbiomarkerdiscovery,
and thus, variable selection relies on the interpretation of the trained
classiﬁers.
One commonly acknowledged problem in biomarker discovery is
that in reality, the lists of marker genes discovered from independent
gene expression proﬁles rarely overlap, although the genes are often
involvedincommonpathways(Chuangetal.,2007;Yuetal.,2007).
For example, in the study of breast cancer, van’t Veer et al. (2002)
and Wang et al. (2005) identiﬁed two sets of marker genes related
to the metastasis of breast cancer using large-scale gene expression
proﬁlesproducedintwodifferentmicroarrayexperiments.However,
there are only three genes in common between the two sets
of the marker genes. Although the non-replicability is partially
introduced by the difference of the microarray platforms and the
experiment techniques used for generating the high-throughput
data, cluster structures or modularities on the genes, such as co-
expression can be used to leverage that discrepancy. However,
it is a computational challenge to explore the cluster structures
amongthefeaturestogetherwiththelabelinformationforbiomarker
discovery.
In this article, instead of selecting features based on their
discriminant power in classifying samples, we propose to use
labeled samples to classify features.We introduce a semi-supervised
learning algorithm to associate clinical variables, gene expressions
and SNPs with speciﬁc phenotypes in a disease context. We
formulate the biomarker discovery task as a ‘hybrid’ semi-
supervised classiﬁcation problem: we use training samples (positive
and negative) to classify both the test samples and the features into
positive, negative or neutral classes (Fig. 1A and B). The positively
classiﬁed features and negatively classiﬁed features are candidate
biomarkers.Thisnewlearningalgorithmcancapturethedependence
between both samples and features (clinical or genetic variables) by
exploring the global structure of the bipartite graph, based on a
‘bi-cluster assumption’: those samples in the same class tend to be
heavily connected to a common set of features; those features that
can characterize a class tend to be heavily connected to the samples
in the class. In the bipartite graph, feature vertices represent clinical
variables, up/down-regulated genes or homozygous or heterozygous
SNPs; object vertices represent labeled and unlabeled samples,
connected to the feature vertices by weighted edges. The object
vertices are labeled with −1/+1 if the label is known, 0 otherwise.
Every clinical variable is denoted by one vertex, and it is connected
to all the samples by the edges weighted by the original clinical
values (Fig. 1C). Every gene is represented by two vertices, up-
regulated and down-regulated; each sample will be connected to
either the up-regulated vertex or the down-regulated vertex with an
edge weighted by the expression level (Fig. 1D). Each SNP will
have three states, two homozygous states and one heterozygous
state; every sample will be connected to one of the three vertices
depending on the SNP type of this sample (Fig. 1E).
Our algorithm is in a family of label propagation algorithms
(Bengio et al., 2006; Zhou et al., 2004), which can be regarded
as semi-supervised spectral graph-learning techniques with a global
optimal solution (Bengio et al., 2006). Recognized as having good
generalization and high efﬁciency, these algorithms are receiving
increasing attention from both machine learning and computational
biology research communities (Kuang et al., 2005; Tsuda et al.,
2005;Weston et al., 2004).The common property of all these graph-
based learning algorithms is the ‘cluster assumption’: there are often
subtle underlying cluster structures in a large graph, which can
be used implicitly to improve classiﬁcation of unlabeled samples.
We formulate the problem differently by classifying objects and
features together. Our formulation implicitly explores the bi-cluster
structure (Cheng and Church, 2000) in the data and labels the
feature vertices based on their connections in the bi-clusters and the
labels on the training samples. The bi-cluster structure can leverage
the classiﬁcation of the features by imposing the modularity on the
features. In other words, features that are in the same bi-cluster tend
to get similarly labeled by our algorithm. This property effectively
utilizes the dependence among all the features for our biomarker
discovery task.
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Ourgraph-basedlearningalgorithmcapturesdependencebetween
allfeaturessimultaneouslybyexploringthegraphstructure,whichis
essentially a non-linear method for selecting features.After relaxing
thelabelsintorealnumbers,ourmethodcanalwaysconvergetoward
the unique global optimum using an efﬁcient network propagation
algorithm.The time complexity of the algorithm scales linearly with
the total number of features given that our algorithm converges
within a small number of iterations. Thus, our method is stable
and fast to generate replicable results across independent datasets,
even under the curse of dimensionality in biomarker identiﬁcation.
Finally, our semi-supervised learning algorithm can use unlabeled
data in the process of classifying the features, which can possibly
improve the quality of the selected features.
2 METHOD
In this section, we ﬁrst deﬁne our formulation of marker discovery
and disease diagnosis/prognosis as a semi-supervised learning problem
on bipartite graphs. An efﬁcient network propagation algorithm is then
introduced to compute the closed-form solution of the objective function
for the semi-supervised learning.
2.1 Semi-supervised learning on bipartite graphs
We formally deﬁne an undirected bipartite graph G=(V,U,E,w), where
V and U are two disjoint vertex sets and E∈V×U is a set of weighted
edges; each edge (v,u)∈E connects two vertices v and u with a positive
weight w(v,u). Let d(v)=
 
(v,u)∈Ew(v,u) and d(u)=
 
(v,u)∈Ew(v,u) denote
the sum of the weights of the edges on the same vertex. Let y:V∪U→
{−1,0,+1}betheinitializationfunctionassigninginitiallabelstothelabeled
and unlabeled vertices in V and U. Let f denote a label-assignment function
over vertex sets V and U.I fw el e tV be the sample set and U be the
variables/featureset,alabelassignmentonavariableindicatesitsassociation
with a sample class. Under this context, we deﬁne an objective function over
G=(V,U,E,w) as follows,
 (f) =
 
(v,u)∈E
w(v,u)
 
f(v)
 
d(v)
−
f(u)
 
d(u)
 2
+ 
 
v∈V
(f(v)−y(v))2+ 
 
u∈U
(f(u)−y(u))2, (1)
where  >0 is a regularization parameter for balancing the cost terms on the
right side of the equation. The ﬁrst term enforces a consistency between the
strongly connected vertex pairs (u,v)∈V×U. This term penalizes those f
functions with a cost proportional to the w(v,u)i ff assigns different labels
to v and u. The second term is a ﬁtting term which keeps the new label
assignment consistent with the initial labeling. This can be viewed as a
supervised way of minimizing the training errors measured by the difference
between the initial labels y(v) and the new label f(v) for labeled vertices
v∈V. For the unlabeled vertices v∈V with y(v)=0, the second term is used
to regularize these f(v)s, such that the total cost is constrained. The third
term is used in the same spirit to constrain the cost on the vertices in U.
If we restrict the labels to discrete values, i.e. f :V∪U→{−1,0,+1},
minimizing  (f) is NP hard. But if we relax the label values as f :V∪U→
R,  (f) is convex and differentiable. Let DU be a diagonal matrix with
Diuiu =d(u) and DV be a diagonal matrix with Diviv =d(v), where v∈V and
u∈U, and iv and iu are the index of vertices u and v in the matrix. We deﬁne
the normalized connectivity matrix S of G as follows,
S=

 0 D
− 1
2
V ∗W ∗D
− 1
2
U
D
− 1
2
U ∗WT ∗D
− 1
2
V 0

,
where W denotes a |V| by |U| matrix with Wiv,iu =w(v,u). Similar to the
derivation in Zhou et al. (2004), we can rewrite Equation (1) as follows,
 (f) =[ f(V)T f(U)T]∗(I−S)∗
 
f(V)
f(U)
 
+ 
 
 
 
 
 
f(V)
f(U)
 
−
 
y(V)
y(U)
  
 
 
 
2
,
where I is the identity matrix. We then differentiate  (f) with respect to f
to compute the closed-form solution f ∗ for minimizing  (f),
∂ 
∂f
=2(I−S)∗f ∗ +2 (f ∗−y)=0.
Let α=1/(1+ ) and after rearrangement, the closed-form solution f ∗ can
be computed as follows,
f ∗=
 
1+ 
 
I−
1
1+ 
S
 
∗y=(1−α)(I−αS)−1∗y. (2)
2.2 Network propagation algorithm
It is computationally intensive to compute the matrix inverse in Equation (2),
when the graph G is large and contains a lot of non-zero entries in S.
Weuseanetworkpropagationalgorithmtocomputetheclosed-fromsolution
more efﬁciently. The propagation algorithm iteratively performs a diffusion
operation between the two vertex sets in both directions. Theoretically, the
diffusion process will ﬁnally converge to the closed-form solution f ∗ deﬁned
inEquation(2).Thenetworkpropagationalgorithmisdescribedasfollows.
(1) Normalize the bipartite graph by computing B=D
− 1
2
V ∗W ∗D
− 1
2
U .
(2) Choose parameter α and perform a two direction propagation, until
convergency (t denotes the time step):
• For each v∈V,
f(v)t =(1−α)y(v)+α
 
u∈UBiviuf(u)t−1
• For each u∈U,
f(u)t =(1−α)y(u)+α
 
v∈VBiviuf(v)t−1
(3) The sequence f t converges to its limit f ∗ and f ∗ gives the class labels
on the unlabeled vertices in both V and U.
This algorithm propagates the label information of every vertex to its
neighbors in the other vertex set. This propagation process will leverage
the activation values of the vertices in a densely connected neighborhood.
In other words, if we assume that the vertices with the same label tend to
be in the same clusters in the graph, the vertices in the same class will
eventually converge to having similar values (same labels). This iterative
propagation process was originally proposed to spread the activation values
in a psychology network (Shrager et al., 1987). It is intuitively consistent
with the deﬁnition of our objective function in Equation (1). In Figure 1C,
we show the predictions of network propagation on a toy graph. Note that
in the method by Kuang et al. (2005), a similar algorithm has been used for
protein ranking, but the normalization of S is different and no regularization
framework was introduced.
We can show that this algorithm will ﬁnally converge to the closed-form
solutionoftheobjectivefunction (f).Weﬁrstrewritethenetworkdiffusion
algorithm in matrix form as,
f(V)t = (1−α)y(V)+αB∗f(U)t−1
f(U)t = (1−α)y(U)+αBT ∗f(V)t−1,
which can be rearranged as f t =(1−α)y+αS∗f t−1. Following the proof by
Zhouetal.(2004),wecanshowthatf convergestof ∗=(1−α)(I−αS)−1∗y,
which is exactly the closed-form solution in Equation (2).
The time complexity of the network propagation algorithm is
O(k|V||U|), where k is the number of iterations for reaching convergence.
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Theoretically, k depends on some properties of the graph such as the
eigenvalues of its Laplacian (Bengio et al., 2006). Empirically, we observe
that our network propagation algorithm converges very fast on the bipartite
graphs in our experiments. For example, when the convergence is deﬁned
as the maximum change of activation values over all the graph nodes being
smaller than 1e−9, our algorithm converges between 10 and 200 iterations,
depending on the choice of the α parameter, on a dataset with 24000 gene
expressions (about 48000 features in the graph) .
3 EXPERIMENTS
We evaluated the network propagation algorithm on three public
breast cancer datasets. We ﬁrst show that our algorithm is a highly
competitive classiﬁcation algorithm in Section 3.2, and then we
show that our algorithm identiﬁes highly reproducible marker genes
on independent microarray datasets in Section 3.3. We also analyze
the convergence rate and measure the empirical running time of
the network propagation algorithm in Section 3.4. Finally, we
validate the marker genes identiﬁed by network propagation by
comparing with known cancer genes in the literature and checking
their biological functions in Section 3.5.
3.1 Breast cancer datasets
We used three independent large-scale microarray gene expression
breast cancer datasets (van de Vijver et al., 2002; van’t Veer et al.,
2002; Wang et al., 2005) in our experiments. The three datasets
were generated for studying breast cancer metastasis. The dataset
(Rosetta dataset) in van’t Veer et al. (2002) measures expression
proﬁles of 24481 genes generated by Agilent (Santa Clara, CA)
oligonucleotide Hu25K microarrays as well as eight clinical
variables: age, estrogen receptor positive (ERp), progesterone
receptor positive (PRp), tumor size, tumor grade, angioinvasion,
lymphocytic inﬁltration and BRCA1 mutation.This dataset contains
97 patient samples. Among the 97 patients, 51 patients had a good
prognosis, meaning being free of disease after their diagnosis for
an interval of at least 5 years, and 46 patients had developed
distant metastasis within 5 years. The van de Vijver et al. (2002)
dataset contains microarray gene expressions produced by the same
technique for generating the Rosetta dataset on 295 samples (194
with good outcome and 101 with poor outcome). The details of the
quantization and normalization of the scanned microarray images
of the two datasets are described in van’t Veer et al. (2002) and
van de Vijver et al. (2002). The Wang et al. (2005) dataset was
produced by the Affymetrix oligonucleotide microarray U133a
GeneChip.Theexpressionof22283transcriptswerecollectedfrom
total RNA of frozen samples from 286 lymph-node-negative breast
cancer patients. Among the 286 patients, 95 had developed cancer
metastasis within 5 years and 114 had been free of metastasis for at
least 8 years. These two groups of patients (209 in total) are used
in our experiments. We normalized the Wang et al. dataset with
GeneSpring (version 7.0) by per-gene and per-chip median polish.
3.2 Sample classiﬁcation
To validate that the identiﬁed discriminant features are indeed
strongly correlated with the patient classes and can be used to
classify samples accurately, we measured the classiﬁcation results
on the test samples. We compared the classiﬁcation performance
of the network propagation algorithm against SVMs with RBF
kernel and linear kernel (Vapnik, 1998), linear discriminant analysis
Table 1. Sample classiﬁcation
Algorithms Rosetta Vijver Wang
Clinical Genes Genes Genes
(A) Classiﬁcation results on three datasets
Network propagation 0.788 0.740 0.667 0.564
SVM (linear) 0.773 0.730 0.662 0.536
SVM (RBF) 0.783 0.737 0.661 0.568
Naïve Bayes 0.795 0.617 0.476 0.554
LDA 0.579 0.740 0.648 0.502
(B) Comparison between network propagation
and the baseline algorithms
NP versus SVM 278/31/191 247/27/226 242/86/172 309/25/166
(linear)
NP versus SVM 248/44/208 214/124/162 254/81/165 137/130/233
(RBF)
NP versus Naïve 144/106/250 393/10/97 466/3/31 261/24/215
Bayes
NP versus LDA 460/8/32 232/36/232 297/61/142 359/15/126
Panel A: the mean ROC scores of classifying patients with good/poor prognosis in the
Rosettadataset,thevandeVijveretal.datasetandtheWangetal.datasetusingnetwork
propagation (NP), SVMs with linear and RBF kernels, naïve Bayes classiﬁer and LDA.
The two best performing algorithms in each experiment are marked in bold.
Panel B: the number of times of win/draw/loss on classiﬁcation performance between
network propagation and the baseline algorithms.
(LDA) and naïve Bayes classiﬁer. The classiﬁcation performance
is evaluated using the receiver operating characteristics (ROC)
score: the normalized area under a curve plotting the number of
true positives against the number of false positives by varying a
threshold on the decision values (Gribskov and Robinson, 1996). In
all experiments, we run 5-fold cross-validation on the whole dataset.
An additional cross-validation on the training set is used to select
the best parameters and we compute ROC scores on the test set. We
repeated the process 100 times and report the mean and the variance
of the ROC scores for each method.
We tested the classiﬁcation performance of the network
propagation algorithm on the three datasets in four different
experiment setups: (1) using eight clinical variables on the Rosetta
dataset; (2) using all 24481 gene expressions on the Rosetta dataset;
(3) using all 24481 gene expressions on the van de Vijver et al.
(2002) dataset; (4) using all 22283 gene expressions on the Wang
et al. (2005) dataset. We prune the gene expression features with
a cutoff of 0.3 on the absolute values of correlation coefﬁcients
calculated on the training samples in Experiment (2) and (3) and
0.2 in Experiment (4). In Table 1(Panel A), we report the mean
of the ROC scores computed from 100 runs of 5-fold cross-
validation on each dataset. The variance of all the methods are
similar in each experiment, and are thus reported in Supplementary
Tables 1–5. In Table 1(Panel B), we also report how many times
network propagation wins or loses to the others. For a more rigorous
comparison, we calculated the P-values with one-sided paired t-test
orproportiontesttoevaluatewhethernetworkpropagationperforms
better than the other algorithms over 100 runs of randomized 5-fold
cross-validations. Overall the proposed network propagation has
very competitive performance (see Supplementary Tables 1–5 for
details).
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The results in Table 1(Panel A) show that in all experiments,
network propagation is always among the two best performing
algorithms. Although the naïve Bayes classiﬁer performs best on
the clinical data, it does not handle gene expression data well in
the other three experiments. LDA does not perform well on the
clinical data; furthermore, it is the worst performing algorithm
on Wang et al. dataset. SVM with linear kernel and RBF kernel
also perform stably well in all experiments. Although SVM with
RBF kernel achieves the highest average ROC scores on the Wang
et al. dataset and SVM with linear kernel is the best performing
algorithm on the van de Vijver et al. dataset, network propagation
is the best performing algorithm in the other two experiments. It
appears that the difference between the performance of network
propagation and SVMs are marginal if only measured by the mean
ROC scores. However, the pairwise comparison between network
propagation and SVMs shows that the differences are statistically
signiﬁcant either by the number of loss and win or by P-values.
The comparisons with the baseline algorithms show that network
propagation is a competitive classiﬁcation algorithm for cancer
outcome prediction and statistically, network propagation also has
more robust performance in the four experiments.
3.3 High reproducibility of marker genes
To verify that network propagation identiﬁes highly reproducible
marker genes on independent microarray datasets, we report the
number of common marker genes identiﬁed in the van de Vijver
et al. dataset and Wang et al. dataset. Since the gene expressions
in the two datasets are produced on different microarray platforms,
there are only 8733 common genes that can be matched by the probe
names. Thus, in this analysis we focus on using the labels of all the
patients to identify the marker genes from the 8733 common genes
independently on the two datasets.
Afterwerannetworkpropagationtoclassifythegenefeatures,we
ranked the genes by the absolute value of their z-scores calculated
from the activation values. We compared the percentage of common
genes between the top-ranked genes in the two datasets identiﬁed by
each method in Figure 2. We tested network propagation with three
different α-values (0.95, 0.5 and 0.1) and compared them with the
commonly used correlation coefﬁcients for identifying differentially
expressed genes, SVM with linear kernel and the random case.
Therandomcaseiscalculatedbytheaverageratioofcommongenes
identiﬁedbynetworkpropagationonbipartitegraphswithrandomly
permuted edges.
It is clear in Figure 2 that network propagation identiﬁes
signiﬁcantly more reproducible marker genes on the two datasets.
For example, among the top-100 genes selected by network
propagation from the two datasets, there are 32 common genes
when α=0.95, 14 common genes when α=0.5 and 6 common
genes when α=0.1, while SVM with linear kernel and correlation
coefﬁcients can only identify two common genes. One interesting
observation is that the α parameter strongly inﬂuences the
percentage of common genes: the larger the α parameter, the
more the common genes identiﬁed. This can be explained by
our optimization formulation in Equation (1); when α is large,
we put more weight on the cluster structures in the bipartite
graph and thus, network propagation favors the modularity
structure in the gene expressions by assigning highly consistent
weights to the coexpressed genes. In other words, those genes
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Fig. 2. Common marker genes identiﬁed by network propagation on the van
de Vijver et al. dataset and the Wang et al. dataset. The x-axis is the number
of selected marker genes ranked by z-scores converted from their activation
values. The y-axis is the percentage of the overlaps between the selected
markers from the two datasets.
that are highly coexpressed in the related functional modules
will get highly weighted in both datasets. When α is close to 1,
our algorithm almost becomes a completely unsupervised learning
algorithm; on the contrary, when α is close to 0, our algorithm
is similar to computing correlation coefﬁcients for the features.
Because our algorithm uses both cluster structures and label
informationtoidentifymarkergenes,itcanretrievemoreoverlapped
marker genes than those methods that ignore the dependence among
the gene features, such as correlation coefﬁcients and SVM with
linear kernel. Our result also implies that on the two microarray
datasets, although the overlap between the rankings of genes is
almost random if the signiﬁcance is computed independently, the
modular structures between genes are still preserved. Network
propagation is an effective way of exploring the modular structures
to produce a more reliable gene ranking.
3.4 Convergence rate and running time
To test the convergence and the scalability of our network
propagation algorithm, we measured the convergence rate and the
running time of network propagation on the Rosetta dataset (97
samples,24481genes),thevandeVijveretal.dataset(295samples,
24481 genes) and the Wang et al. dataset (209 samples, 22283
genes). We deﬁne the convergence as the maximum change of
activation values over all the graph nodes being smaller than 1e−9.
Theoretically, the convergence rate is decided by the Laplacian of
the bipartite graph, which in our case is strongly related to the
choice of the α parameter. We tested nine different α parameters
and reported the running time and the number of iterations for
reaching convergence in Figure 3. For all the choices of α parameter
on the three datasets, network propagation converges within 200
iterations. When α is small, the algorithm converges in very few
iterations. Intuitively, this can be explained by the nature of network
propagation: when α is large, the propagation operation puts more
weight on the graph structure and less weight on the relatively static
label information, and it takes more iterations to fully explore the
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Fig. 3. Convergence and running time of network propagation. This plot
shows the convergence rate and the running time of the network propagation
algorithm on the three microarray datasets. The x-axis is the values of the
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whole structure, given a certain threshold on the contribution of
change on the activation values from the subtle structure of the
bipartite graph. It is notable that on a regular PC, our algorithm only
needs at most 103s to reach a convergence for the datasets with
more than 24000 genes.
Empirically we observed that for any choice of α, the number of
iterations that network propagation takes to converge is independent
of the number of genes in the dataset. Thus, the running time of the
algorithm is approximately linear in the number of genes in the
dataset. To verify this hypothesis, we randomly selected a certain
number of genes from the van de Vijver et al. dataset and tested
our network propagation algorithm for three different α values. The
result is reported in Supplementary Figure 1. Clearly, in all the
three cases, the actual running time scales linearly in the number
of selected genes.
3.5 Biological interpretations of marker genes
We compared the identiﬁed marker genes from all the genes in the
van de Vijver et al. dataset and the Wang et al. dataset with previous
ﬁndings in the literature. We also report the over-represented Gene
Ontology functions by the selected marker genes. Finally, to assess
the statistical signiﬁcance of our results, we estimated P-values
for the activation values of the marker genes by running network
propagation on bipartite graphs with randomized edges. In all the
experiments in this section, we used the label on all the patients to
classify all the gene feature vertices. We chose α=0.5 to have a
balanced contribution from label information and graph structures.
With a false discovery rate 0.18 and 0.1 on the van de Vijver
et al. dataset and the Wang et al. dataset, respectively, we selected
the top-200 genes in both datasets as marker genes for a consistent
comparison. We used Ingenuity (version 5.5) to analyze the marker
genes. Out of the top-200 genes ranked by network propagation
(α=0.5)inthevandeVijveretal.datasetandtheWangetal.dataset,
only141genesand140genes,respectively,areeligibleforsearching
the biological networks and annotations provided by Ingenuity. Our
analysis focuses on the 141 and 140 eligible marker genes from the
two datasets. Fifteen genes are in common between the 141 and 140
marker genes. Interesting examples in the 15 common genes are
trefoil factor 1 (TFF1) and transmembrane 4L-six-family member
1 (TM4SF1). The expressions of TFF1 and TM4SF1 are decreased
by breast cancer 1 early onset (BRCA1) and estrogen receptor 1
(ESR1), both of which are well-known breast cancer susceptibility
genes. In comparison with the 15 common genes identiﬁed by
network propagation, there is only one common gene between the
top-200 genes ranked by correlation coefﬁcients on the two datasets.
The higher ratio of overlapped genes also indicates that network
propagation captures the dependence between the genes of similar
roles in those biological networks, and thus ﬁnds more common
pathways associated with a disease from heterogenous datasets.
From the marker genes on the van de Vijver et al. dataset and
the Wang et al. dataset, Ingenuity reports 92 (out of 141) and 51
(out of 140) genes as cancer-related genes, respectively. In the list
of marker genes identiﬁed from van de Vijver et al. dataset, some
interesting examples are v-erb-b2 erythoroblastic leukemia viral
oncogene homolog 2 (ERBB2), baculoviral IAPrepeat-containing 5
(BIRC5) and matrix metallopeptidase 9 (MMP9). ERBB2 is one of
the well-known breast cancer susceptibility genes. The amplication
of the ERBB2 oncogene is found in around 30% of human breast
cancers and used as a target of therapy (van de Vijver et al., 2002;
van’t Veer et al., 2002). The expression of BIRC5 is regulated by
otherwell-knownbreastcancersusceptibilitygenessuchasestrogen
receptor 1, ER-α (ESR1) and TP53. MMP9 is known for promoting
breastcancermetastasis.Weﬁndothermarkergenesinteractingwith
known breast cancer susceptibility genes such as repromo, TP53-
dependent G2 arrest mediator candidate (RPRM) and prominin 1
(PROM), both of which are regulated by ESR1, and Cbp/p300-
interacting transactivator (CITED1), which regulates ESR1, ESR2
and ERBB2. In the list of marker genes identiﬁed from the Wang
et al. dataset, androgen receptor (AR) is known for association
with survival of breast cancer patients; complement component 4
binding protein-beta (C4BPB), cadherin 3 (CDH3) and E74-like
factor 5 (ELF5) are regulated by ERBB2 and MAGEA2. ERBB2
and MAGEA2 are known to be able to decrease trans-activation
activity of TP53. The activities of other genes in the list such as
Thymosin-like 8 (TMSL8), POU class 4 homeobox 1 (POU4F1),
stratiﬁn (SFN) and prominin 1 (PRPM1) also involve TP53. We
also found that, although some known breast cancer susceptibility
genes are not included in the marker genes, their neighbor genes
that are known to interact with them are identiﬁed. Two examples
are v-myc myelocytomatosis viral oncogene homolog (MYC) and
v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS).
We report identiﬁed functions associated with our marker genes in
Supplementary Tables 6–7.
Ingenuity identiﬁed 19 and 13 enriched functions scoring a
P-value <0.01 and involving at least two marker genes on the van
de Vijver et al. dataset and the Wang et al. dataset, respectively
(Supplementary Tables 6–7). In Figure 4, we list the 11 common
functions between the 19 and 13 enriched functions in the two
datasets.The enriched functions show strong consistency with those
identiﬁed by Hanahan (2000) and Wang et al. (2005), which have
been shown to be signiﬁcantly involved with the progression of
cancer. Among the 11 functions, eight functions such as cellular
growth and proliferation, cell death, cell cycle and, etc., are exactly
or closely matched with the 21 functions discovered previously in
Wang et al. (2005) (See Supplementary Tables 6–7).
To estimate the statistical signiﬁcance of the marker genes,
we compared the activation value on the k-th ranked feature
vertex with its background distribution computed from 500 runs of
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Fig. 4. Biological functions enriched by the markers genes identiﬁed by
network propagation on the van de Vijver et al. dataset and the Wang et al.
dataset. We list the functions scoring a P-value <0.01 and involving at least
two marker genes on both datasets. The functions are sorted by P-values
calculated using the right-tailed Fisher exact test.
network propagation with randomized graph edges. Speciﬁcally, we
randomizethegraphedgesbymovingtheedgestoconnectrandomly
selected samples and feature vertices. We ran network propagation
on the random graphs and repeated it 500 times. For each random
graph, we ranked the feature vertices by their activation values.
We then used the 500 values on each k-th ranked feature vertex as a
sample of the background distribution for obtaining the k-th rank in
the list. We compared our observed activation values on the van de
Vijver et al. dataset and the Wang et al. dataset with their respective
backgrounddistributionsbyestimatingP-valuesandscatterplotting.
In Supplementary Figure 3, we show the scatter plot of the observed
activation values and the expected activation values on the van de
Vijver et al. dataset and the Wang et al. dataset. In the plots, clearly
the largest and the smallest activation values signiﬁcantly deviate
from the expected values. In Supplementary Table 8, we list the top-
50 marker genes identiﬁed on two datasets along with their P-values
(See Supplementary website for the full list).
4 DISCUSSION
In this article, we present a new machine learning framework
for supervised biomarker identiﬁcation, in which we classify the
features into ‘positive’, ‘negative’ and ‘neutral’ classes. We also
design an efﬁcient semi-supervised graph-based learning algorithm
to compute the global optimal solution of this feature classiﬁcation
problem. In our experiments, we show that our algorithm can
generate highly reproducible marker genes in two independent
breast cancer datasets; we also show that our algorithm can handle
hundreds of thousands of features simultaneously in <2min on
a regular PC. One limitation of our current algorithm is that no
prior knowledge on the dependence between the feature vertices
such as linkage disequilibrium between SNPs, is used in the
process of classifying features. We plan to design new algorithms
that can utilize the dependence between the features as prior
knowledge by running network propagation on graphs of more
sophisticated topologies. Another limitation is that, although the
network propagation algorithm demonstrates high performance
in classiﬁcation, no improvement has been achieved from data
integration (Supplementary Table 3). We postulate that naïve linear
concatenation of different types of features is not a principled data-
integrationstrategyforthenetworkpropagationalgorithm.Thus,we
are also designing new algorithms that can integrate different graphs
inanon-linearmanner.Ithasrecentlybeenshownthatpathwaysand
protein–proteininteractionnetworkscanimprovethereproducibility
of the marker genes (Chuang et al., 2007). However, availability of
pathway and protein–protein interaction data is often very limited.
Our method can capture the modularity of the genes without using
any extra information.
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